Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A study in mice found that engineered "bacterial biosensors” could detect DNA shed by colorectal cancer tumors.
A University of Colorado cancer researcher shows that overexpression of transcription factor Sox9 results in resistance to immunotherapy.
Barb Spanjer worked with a University of Colorado Cancer Center multidisciplinary team on a personalized, multi-front treatment plan.
KRAS has been one of the most hard-to-hit targets in cancer research.
A potential pancreatic cancer treatment might not only inhibit the KRAS-MAPK pathway but also disrupt a breakdown of iron, research shows.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
The new approach takes advantage of the natural process by which cells break down proteins into fragments called peptides.
Promising research shows that marking the mutated KRAS protein of cancer cells can signal the immune system to destroy that cancer.
The median progression- free survival time was 6.5 months, and the median overall survival time was 12.6 months.
Experimental KRAS inhibitor adagrasib also shows activity against lung cancer that has spread to the brain.
Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Damon Runyon Cancer Research Foundation scientists work to develop drugs for people with KRAS-driven cancers.
Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.
Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.